ModerateVitamin K antagonist anticoagulants×Third-generation oral cephalosporin
Updated · Methodology
Mechanism
Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list second- and third-generation cephalosporins among antibiotics that can potentiate acenocoumarol. The cefditoren SmPC classifies cefditoren (cefditoren pivoxil) as a third-generation cephalosporin (acenocoumarol and cefditoren SmPCs, AEMPS). According to the cefditoren SmPC, prothrombin activity can fall during cephalosporin treatment. The US label also counts people previously stabilised on anticoagulant therapy among those at risk (cefditoren SmPC, AEMPS; cefditoren prescribing information, US Food and Drug Administration, FDA). In clinical trials, the incidence of prolonged prothrombin time did not differ between cefditoren and comparator cephalosporins (FDA). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).
Symptoms
The main risk is bleeding. Rare adverse effects of cefditoren include prolonged coagulation time, thrombocytopenia and gastrointestinal bleeding (cefditoren summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label lists bleeding and prolonged prothrombin time among adverse reactions of the whole cephalosporin class (cefditoren prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints (AEMPS).
Management
The combination is not contraindicated but needs frequent coagulation monitoring. The acenocoumarol summaries of product characteristics (SmPCs) ask for close and frequent coagulation checks, for example twice a week. This applies both when cefditoren is added and when it is stopped, including after the end of the antibiotic course (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). In people taking anticoagulants, monitor the prothrombin time during cefditoren treatment (cefditoren SmPC, AEMPS). The US label says to give vitamin K as indicated (cefditoren prescribing information, US Food and Drug Administration, FDA). Adjust the acenocoumarol dose by the prothrombin time and the international normalised ratio (INR). A dose change does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. After bleeding, restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.4 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.4 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.4
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.2
- AEMPS: Ficha técnica: Cefditoreno pivoxilo, Meiact 200 mg (nº registro 65943), secciones 4.4 y 5.1 (2026)– AEMPS, CIMA, nº registro 65943 (Meiact 200 mg comprimidos recubiertos con película, Meiji Pharma Spain; mismo texto en Meiact 400 mg, nº 65975, y Spectracef 200 y 400 mg, nº 65942 y 65973), revisión 04/2026, secciones 4.4, 4.8 y 5.1
- FDA: Spectracef (cefditoren pivoxil) prescribing information (2013)– FDA, DailyMed setid 1c90b649-5536-417c-82cb-89663137f14f (Vansen Pharma), versión 2, 06/2013, Contraindications, Precautions (General, Drug Interactions), Adverse Reactions